Imagine a world where a child’s first steps or first words remain just out of reach, not because of typical developmental delays, but due to a rare and devastating condition. This is the reality for families affected by CDKL5 deficiency disorder (CDD), a severe developmental and epileptic encephalopathy (DEE) that impacts approximately 1 in 40,000 to 60,000 live births. But here’s where it gets even more heart-wrenching: CDD doesn’t just steal milestones—it unleashes a relentless storm of drug-resistant seizures, neurodevelopmental challenges, and a lifetime of uncertainty for both patients and their families.
The Seizure Storm: A Battle Against the Unpredictable
From the earliest months of life, children with CDD face frequent and often uncontrollable seizures. These aren’t your typical seizures—they’re fiercely resistant to medication, forcing families to juggle multiple anti-seizure drugs with limited success. And this is the part most people miss: even with treatment, seizures persist daily for most patients. The types of seizures evolve over time, starting with epileptic spasms or tonic seizures in infancy and later expanding to include focal and generalized seizures. It’s a moving target, making management even more daunting.
Beyond Seizures: The Hidden Layers of CDD
But CDD isn’t just about seizures—it’s a complex web of challenges. Children with CDD often experience profound neurodevelopmental delays, affecting cognition, motor skills, speech, sleep, and even gastrointestinal and visual function. For many, walking or speaking remains a distant dream. Gastrointestinal issues frequently lead to the need for feeding tubes, while sleep disturbances, scoliosis, and vision problems add layers of complexity to daily life. It’s a condition that demands constant adaptation and resilience.
The Family Toll: A Life on Hold
For parents, CDD means becoming full-time caregivers, advocates, and therapists. The emotional and practical burden is immense, often forcing them to pause their careers, shrink their social circles, and dedicate every waking moment to their child’s care. The sense of isolation is palpable, compounded by the lack of a specific treatment for CDD. Nearly half of individuals with CDD take three or more anti-seizure medications, yet seizure control remains elusive for most. And here’s the controversial question: Are we doing enough to support these families, or is the rarity of CDD leaving them behind?
Diagnosis Delays: A Missed Opportunity?
Because CDD is so rare and complex, diagnosis is often delayed. This means families miss out on early access to specialized care and support networks, amplifying their struggles. But what if earlier diagnosis could change the trajectory for these families?
A Glimmer of Hope: Progress on the Horizon
At this year’s American Epilepsy Society Congress, we shared promising phase 3 data for CDD, fueled by the unwavering resilience of families who refuse to give up. These champions inspire us daily to push the boundaries of science and address the significant unmet needs in CDD. Yet, the journey is far from over. What role do you think awareness and advocacy play in accelerating progress for rare conditions like CDD?
Looking Ahead: A Call to Action
Together, we can raise awareness, advance solutions, and ensure no family faces CDD alone. By sharing stories, supporting research, and fostering community, we can create a brighter future for those affected by CDD. But here’s the final thought: What’s one small step you can take today to make a difference? Let’s start the conversation in the comments—your voice matters.
